Bryan D. Marks

566 total citations
17 papers, 442 citations indexed

About

Bryan D. Marks is a scholar working on Molecular Biology, Oncology and Pharmacology. According to data from OpenAlex, Bryan D. Marks has authored 17 papers receiving a total of 442 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 6 papers in Oncology and 6 papers in Pharmacology. Recurrent topics in Bryan D. Marks's work include Pharmacogenetics and Drug Metabolism (6 papers), Computational Drug Discovery Methods (4 papers) and Drug Transport and Resistance Mechanisms (3 papers). Bryan D. Marks is often cited by papers focused on Pharmacogenetics and Drug Metabolism (6 papers), Computational Drug Discovery Methods (4 papers) and Drug Transport and Resistance Mechanisms (3 papers). Bryan D. Marks collaborates with scholars based in United States, Norway and United Kingdom. Bryan D. Marks's co-authors include Olga V. Trubetskoy, Steven M. Riddle, William J. Frazee, Kurt W. Vogel, Mary Szatkowski Ozers, Connie S. Lebakken, Upinder Singh, Mohammed Saleh Shekhani, Mei‐Fei Yueh and Judy L. Raucy and has published in prestigious journals such as Blood, Biochemistry and Cancer Research.

In The Last Decade

Bryan D. Marks

16 papers receiving 412 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bryan D. Marks United States 13 244 138 83 60 52 17 442
Ann‐Charlotte Egnell Sweden 8 218 0.9× 182 1.3× 96 1.2× 87 1.4× 33 0.6× 11 474
Cameron D. Buchman United States 10 194 0.8× 84 0.6× 106 1.3× 40 0.7× 38 0.7× 11 363
Suzanne Tay United States 10 166 0.7× 144 1.0× 112 1.3× 40 0.7× 54 1.0× 15 408
Mary Zoeckler United States 11 180 0.7× 173 1.3× 203 2.4× 27 0.5× 66 1.3× 14 485
Valeria Chu United States 15 123 0.5× 86 0.6× 68 0.8× 40 0.7× 17 0.3× 31 544
Paul Shapiro United States 18 469 1.9× 34 0.2× 124 1.5× 107 1.8× 24 0.5× 31 669
Douglas Ferguson United Kingdom 14 185 0.8× 133 1.0× 142 1.7× 63 1.1× 19 0.4× 28 615
Mary J. Kuffel United States 14 272 1.1× 190 1.4× 262 3.2× 37 0.6× 249 4.8× 30 734
Daniel C. Kemp United States 9 179 0.7× 133 1.0× 124 1.5× 20 0.3× 63 1.2× 11 488
Lance Goulet United States 11 379 1.6× 109 0.8× 81 1.0× 54 0.9× 9 0.2× 14 639

Countries citing papers authored by Bryan D. Marks

Since Specialization
Citations

This map shows the geographic impact of Bryan D. Marks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bryan D. Marks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bryan D. Marks more than expected).

Fields of papers citing papers by Bryan D. Marks

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bryan D. Marks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bryan D. Marks. The network helps show where Bryan D. Marks may publish in the future.

Co-authorship network of co-authors of Bryan D. Marks

This figure shows the co-authorship network connecting the top 25 collaborators of Bryan D. Marks. A scholar is included among the top collaborators of Bryan D. Marks based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bryan D. Marks. Bryan D. Marks is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Khetarpal, Vinod, Ignacio Muñoz-Sanjuán, Cristina Sampaio, et al.. (2024). Lack of evidence for kynurenine pathway dysfunction in Huntington's disease: Cerebrospinal fluid and plasma analyses from the HDClarity study. Journal of Huntington s Disease. 14(1). 85–92.
2.
Khetarpal, Vinod, Shahzad Akhtar, Zhixin Miao, et al.. (2023). Validation of LC–MS/MS Methods For Quantitative Analysis of Kynurenine Pathway Metabolites in Human Plasma and Cerebrospinal Fluid. Bioanalysis. 15(11). 637–651. 1 indexed citations
3.
O’Hare, Thomas, Christopher A. Eide, Anupriya Agarwal, et al.. (2013). Threshold Levels of ABL Tyrosine Kinase Inhibitors Retained in Chronic Myeloid Leukemia Cells Determine Their Commitment to Apoptosis. Cancer Research. 73(11). 3356–3370. 23 indexed citations
4.
Marks, Bryan D., et al.. (2011). A Substrate-Independent TR-FRET Histone Deacetylase Inhibitor Assay. SLAS DISCOVERY. 16(10). 1247–1253. 16 indexed citations
5.
O’Hare, Thomas, Christopher A. Eide, Lauren T. Adrian, et al.. (2011). Cryptic Intracellular Retention of ABL Tyrosine Kinase Inhibitors within CML Cells Mediates Apoptosis Commitment Following Acute Drug Exposure,. Blood. 118(21). 3504–3504. 1 indexed citations
6.
Shukla, Sunita J., Ðắc-Trung Nguyễn, Ryan MacArthur, et al.. (2009). Identification of Pregnane X Receptor Ligands Using Time-Resolved Fluorescence Resonance Energy Transfer and Quantitative High-Throughput Screening. Assay and Drug Development Technologies. 7(2). 143–169. 45 indexed citations
7.
Lebakken, Connie S., Steven M. Riddle, Upinder Singh, et al.. (2009). Development and Applications of a Broad-Coverage, TR-FRET-Based Kinase Binding Assay Platform. SLAS DISCOVERY. 14(8). 924–935. 68 indexed citations
8.
Piper, David R., William J. Frazee, Elizabeth A. Frey, et al.. (2008). Development of the Predictor hERG Fluorescence Polarization Assay Using a Membrane Protein Enrichment Approach. Assay and Drug Development Technologies. 6(2). 213–223. 37 indexed citations
9.
Vogel, Kurt W., et al.. (2008). Facile Conversion of FP to TR-FRET Assays using Terbium Chelates:Nuclear Receptor Competitive Binding Assays as Examples. Letters in Drug Design & Discovery. 5(6). 416–422. 9 indexed citations
10.
11.
Ozers, Mary Szatkowski, Bryan D. Marks, Krishne Gowda, et al.. (2006). The Androgen Receptor T877A Mutant Recruits LXXLL and FXXLF Peptides Differently than Wild-Type Androgen Receptor in a Time-Resolved Fluorescence Resonance Energy Transfer Assay. Biochemistry. 46(3). 683–695. 45 indexed citations
12.
Marks, Bryan D., et al.. (2005). Multiparameter Analysis of a Screen for Progesterone Receptor Ligands: Comparing Fluorescence Lifetime and Fluorescence Polarization Measurements. Assay and Drug Development Technologies. 3(6). 613–622. 16 indexed citations
13.
Trubetskoy, Olga V., et al.. (2005). A simultaneous assessment of CYP3A4 metabolism and induction in the DPX-2 cell line. The AAPS Journal. 7(1). E6–E13. 41 indexed citations
14.
15.
16.
Marks, Bryan D., et al.. (2003). High-Throughput screeening assays for CYP2B6 metabolism and inhibition usuing fluorogenic vivid substrates. PubMed. 5(2). 88–98. 16 indexed citations
17.
Marks, Bryan D., et al.. (2002). A High Throughput Screening Assay to Screen for CYP2E1 Metabolism and Inhibition Using a Fluorogenic Vivid ® P450 Substrate. Assay and Drug Development Technologies. 1(1). 73–81. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ann‐Charlotte Egnell Breakdown of academic impact, for papers by Cameron D. Buchman Breakdown of academic impact, for papers by Suzanne Tay Breakdown of academic impact, for papers by Mary Zoeckler Breakdown of academic impact, for papers by Valeria Chu Breakdown of academic impact, for papers by Paul Shapiro Breakdown of academic impact, for papers by Douglas Ferguson Breakdown of academic impact, for papers by Mary J. Kuffel Breakdown of academic impact, for papers by Daniel C. Kemp Breakdown of academic impact, for papers by Lance Goulet
Rankless by CCL
2026